At close: December 13 at 1:30:37 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,413,305.00
1,204,159.00
899,738.00
864,217.00
2,689,222.00
Cost of Revenue
1,030,089.00
853,836.00
608,559.00
656,128.00
1,414,894.00
Gross Profit
383,216.00
350,323.00
291,179.00
208,089.00
1,274,328.00
Operating Expense
223,280.00
190,023.00
172,209.00
134,431.00
223,929.00
Operating Income
159,936.00
160,300.00
118,970.00
73,658.00
1,050,399.00
Net Non Operating Interest Income Expense
418.00
-2,843.00
-74.00
559.00
4,056.00
Pretax Income
584,242.00
364,190.00
387,820.00
65,506.00
455,215.00
Tax Provision
100,005.00
69,469.00
79,040.00
9,810.00
95,091.00
Net Income Common Stockholders
484,237.00
294,721.00
308,780.00
55,696.00
360,124.00
Diluted NI Available to Com Stockholders
484,237.00
294,721.00
308,780.00
55,696.00
360,124.00
Basic EPS
4.00
2.70
2.88
0.51
3.31
Diluted EPS
3.99
2.69
2.87
0.51
3.28
Basic Average Shares
118,350.25
109,309.00
107,305.00
108,997.62
108,997.62
Diluted Average Shares
118,741.75
109,609.00
107,593.00
109,206.74
109,743.84
Total Expenses
1,253,369.00
1,043,859.00
780,768.00
790,559.00
1,638,823.00
Net Income from Continuing & Discontinued Operation
484,237.00
294,721.00
308,780.00
55,696.00
360,124.00
Normalized Income
483,385.79
296,708.52
321,046.96
53,789.76
371,617.21
Interest Income
6,416.00
3,447.00
998.00
600.00
4,099.00
Interest Expense
5,998.00
6,290.00
1,072.00
41.00
43.00
Net Interest Income
418.00
-2,843.00
-74.00
559.00
4,056.00
EBIT
590,240.00
370,480.00
388,892.00
65,547.00
455,258.00
EBITDA
807,170.00
515,774.00
479,504.00
129,255.00
588,561.00
Reconciled Cost of Revenue
1,030,089.00
853,836.00
608,559.00
656,128.00
1,414,894.00
Reconciled Depreciation
216,930.00
145,294.00
90,612.00
63,708.00
133,303.00
Net Income from Continuing Operation Net Minority Interest
484,237.00
294,721.00
308,780.00
55,696.00
360,124.00
Total Unusual Items Excluding Goodwill
1,027.00
-2,456.00
-15,407.00
2,242.00
-14,528.00
Total Unusual Items
1,027.00
-2,456.00
-15,407.00
2,242.00
-14,528.00
Normalized EBITDA
806,143.00
518,230.00
494,911.00
127,013.00
603,089.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
175.79
-468.48
-3,140.04
335.76
-3,034.79
12/31/2020 - 1/7/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1720.TW Standard Chemical & Pharmaceutical Co. Ltd.
63.00
-1.56%
4108.TW PhytoHealth Corporation
16.10
-2.72%
3705.TW YungShin Global Holding Corporation
54.20
-1.09%
4105.TWO TTY Biopharm Company Limited
73.20
-1.48%
4746.TW Formosa Laboratories, Inc.
71.30
-1.25%
1795.TW Lotus Pharmaceutical Co., Ltd.
261.00
-1.51%
1707.TW Grape King Bio Ltd
152.00
-1.62%
1789.TW ScinoPharm Taiwan, Ltd.
22.20
-2.20%
6472.TW Bora Pharmaceuticals Co., LTD.
751.00
-0.79%
4123.TWO Center Laboratories, Inc.
42.95
-1.72%